Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate
What is Junel Fe?
Junel Fe 24 (norethindrone acetate and ethinyl estradiol tablets USP and ferrous fumarate tablets) is a combination oral contraceptive for oral administration consisting of 24 light yellow active tablets containing norethindrone acetate, USP, a progestin, and ethinyl estradiol, USP, an estrogen, and 4 brown inert tablets containing ferrous fumarate, which serve no therapeutic purpose.
The chemical name of ethinyl estradiol, USP is 19-nor-17α-pregna-1,3,5(10)-trien-20-yne-3,17-diol, and the structural formula is:
CHO M.W. 296.40
The chemical name of norethindrone acetate, USP is 17-hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one acetate, and the structural formula is:
CHO M.W. 340.46
What does Junel Fe look like?
What are the available doses of Junel Fe?
Junel Fe 24 (norethindrone acetate and ethinyl estradiol tablets USP, 1 mg/0.02 mg and ferrous fumarate tablets) consists of 28 tablets in the following order ():
What should I talk to my health care provider before I take Junel Fe?
How should I use Junel Fe?
Junel Fe 24 (norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets) is indicated for use by women to prevent pregnancy
The efficacy of Junel Fe 24 in women with a body mass index (BMI) of > 35 kg/m has not been evaluated.
Junel Fe 24 is dispensed in a blister card . Junel Fe 24 may be started using either a Day 1 start or a Sunday start (see Table 1). For the first cycle of a Sunday Start regimen, an additional method of contraception must be used until after the first 7 consecutive days of administration.
What interacts with Junel Fe?
Sorry No Records found
What are the warnings of Junel Fe?
Sorry No Records found
What are the precautions of Junel Fe?
Sorry No Records found
What are the side effects of Junel Fe?
Sorry No records found
What should I look out for while using Junel Fe?
Do not prescribe Junel Fe 24 to women who are known to have the following conditions:
What might happen if I take too much Junel Fe?
There have been no reports of serious ill effects from overdose of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.
How should I store and handle Junel Fe?
Protect from light. Store at 20° to 25°C (68° to 77°F); excursions permitted from 15° to 30°C (59° to 86°F) .Sucralfate Oral Suspension 1g/10 mL is a pink suspension supplied in the following dosage forms:SHAKE WELL BEFORE USING.AVOID FREEZING.Sucralfate Oral Suspension 1g/10 mL is a pink suspension supplied in the following dosage forms:SHAKE WELL BEFORE USING.AVOID FREEZING.Sucralfate Oral Suspension 1g/10 mL is a pink suspension supplied in the following dosage forms:SHAKE WELL BEFORE USING.AVOID FREEZING.
Chemical StructureNo Image found
COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.
Non-Clinical ToxicologyDo not prescribe Junel Fe 24 to women who are known to have the following conditions:
Some studies have shown that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. Subtherapeutic prothrombin times with concomitant warfarin and sucralfate therapy have been reported in spontaneous and published case reports. However, two clinical studies have demonstrated no change in either serum warfarin concentration or prothrombin time with the addition of sucralfate to chronic warfarin therapy.
The mechanism of these interactions appears to be nonsystemic in nature, presumably resulting from sucralfate binding to the concomitant agent in the gastrointestinal tract. In all cases studied to date (cimetidine, ciprofloxacin, digoxin, norfloxacin, ofloxacin, and ranitidine), dosing the concomitant medication 2 hours before sucralfate eliminated the interaction. Due to Sucralfate Oral Suspension's potential to alter the absorption of some drugs, Sucralfate Oral Suspension should be administered separately from other drugs when alterations in bioavailability are felt to be critical. In these cases, patients should be monitored appropriately.
Thrombotic Disorders and Other Vascular Problems: Stop Junel Fe 24 if a thrombotic event occurs. Stop at least 4 weeks before through 2 weeks after major surgery. Start no earlier than 4 weeks after delivery, in women who are not breastfeeding. ()
Liver disease: Discontinue Junel Fe 24 if jaundice occurs. ()
High blood pressure: If used in women with well-controlled hypertension, monitor blood pressure and stop Junel Fe 24 if blood pressure rises significantly. ()
Carbohydrate and lipid metabolic effects: Monitor prediabetic and diabetic women taking Junel Fe 24. Consider an alternative contraceptive method for women with uncontrolled dyslipidemia. ()
Headache: Evaluate significant change in headaches and discontinue Junel Fe 24 if indicated. ()
Bleeding Irregularities and Amenorrhea: Evaluate irregular bleeding or amenorrhea. ()
The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling:
Adverse reactions commonly reported by COC users are:
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
ProfessionalClonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
InteractionsA total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).